[144] Micron Technology, Inc. SEC Filing
Rhea-AI Filing Summary
Micron Technology, Inc. (MU) – Form 144 filing: An unidentified insider has notified the SEC of an intent to sell up to 80,000 common shares. Based on the indicated price, the aggregate market value of the proposed sale is $9.85 million. The transaction will be executed through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 30 June 2025.
The shares derive from restricted-stock and performance-share grants received between April and October 2024. Micron reports 1.119 billion shares outstanding, so the proposed disposition represents roughly 0.007 % of the float. No sales by the filer occurred during the past three months, and the signer certifies that no undisclosed material adverse information is known.
This notice is procedural under Rule 144; consummation depends on market conditions and compliance with volume and manner-of-sale limits. Given the very small percentage of total shares, the filing is generally viewed as routine with limited market impact.
Positive
- None.
Negative
- Insider intends to sell 80,000 shares valued at $9.85 million, which some investors may interpret as a modest negative sentiment signal despite the immaterial size.
Insights
TL;DR: 80k-share Micron insider sale (~$9.9M) is tiny versus float; market impact likely negligible.
The filing signals an insider’s plan to monetize equity awards received in 2024. At 0.007 % of shares outstanding, the sale sits well below Rule 144 volume thresholds and should not meaningfully affect liquidity or price discovery. Because the issuer has over 1.1 billion shares, daily average trading volume far exceeds the amount offered. While any insider sale can prompt headline risk, the size and scheduled nature (Rule 144, potential 10b5-1 plan) reduce interpretive weight. I view the disclosure as neutral for valuation.
TL;DR: Routine Rule 144 notice; no red flags on governance or undisclosed information.
The signer expressly attests to the absence of material non-public information, satisfying Rule 144 certification. The absence of prior-quarter sales and the use of a recognized brokerage mitigate aggregation or pattern concerns. No governance issues—such as board resignations, litigation, or executive churn—are referenced. Overall, the filing maintains compliance hygiene without signaling governance distress.